RU2004135306A - Новые антитела к тканевому фактору в качестве антикоагулянтов - Google Patents
Новые антитела к тканевому фактору в качестве антикоагулянтов Download PDFInfo
- Publication number
- RU2004135306A RU2004135306A RU2004135306/13A RU2004135306A RU2004135306A RU 2004135306 A RU2004135306 A RU 2004135306A RU 2004135306/13 A RU2004135306/13 A RU 2004135306/13A RU 2004135306 A RU2004135306 A RU 2004135306A RU 2004135306 A RU2004135306 A RU 2004135306A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- seq
- antibody according
- effective amount
- complex
- Prior art date
Links
- 108010000499 Thromboplastin Proteins 0.000 title claims 14
- 102000002262 Thromboplastin Human genes 0.000 title claims 14
- 238000000034 method Methods 0.000 claims 8
- 102100023804 Coagulation factor VII Human genes 0.000 claims 4
- 108010023321 Factor VII Proteins 0.000 claims 4
- 108010014173 Factor X Proteins 0.000 claims 4
- 229940012413 factor vii Drugs 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003114 blood coagulation factor Substances 0.000 claims 2
- 229960004222 factor ix Drugs 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 230000028709 inflammatory response Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
- 108010054265 Factor VIIa Proteins 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002429 anti-coagulating effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 208000002528 coronary thrombosis Diseases 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 229940012414 factor viia Drugs 0.000 claims 1
- 230000001453 nonthrombogenic effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000010118 platelet activation Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/7455—Thrombomodulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (25)
1. Антикоагулирующее антитело, которое связывается с большей аффинностью с комплексом фактор VIIa/тканевый фактор (ТФ), чем со свободным тканевым фактором (ТФ).
2. Антитело по п.1, где антитело обладает по меньшей мере в 2 раза более высокой аффинностью к связыванию с комплексом FVIIa/ТФ, чем со свободным ТФ при измерении с помощью микрокалометрического анализа.
3. Антитело по п.2, где антитело обладает по меньшей мере в 5 раза более высокой аффинностью к связыванию с комплексом FVIIa/ТФ, чем со свободным ТФ.
4. Антитело по п.3, где антитело обладает по меньшей мере в 10 раза более высокой аффинностью к связыванию с комплексом FVIIa/ТФ, чем со свободным ТФ.
5. Антитело по п.1, где антитело представляет собой моноклональное антитело.
6. Антитело по п.5, где антитело представляет собой одноцепочечное антитело, Fab-димерное антитело или антитело в виде IgG.
7. Антитело по п.6, где антитело представляет собой одноцепочечное антитело.
8. Антитело по п.7, где антитело не конкурирует за связывание с ТФ с одним или несколькими факторами свертывания, выбранными из ряда, включающего фактор VII (FVII), фактор IX (FIX) и фактор Х (FX).
9. Антитело по п.8, где факторы свертывания представляют собой FVII и FX.
10. Антитело по п.1, где антитело является гликозилированным.
11. Антитело по п.1, где антитело модифицируют путем добавлением полиэтиленгликоля.
12. Антитело по п.1, где антитело биотинилируют для связывания со стрептавидином.
13. Фармацевтическая композиция, содержащая антитело по п.1, где композиция включает фармацевтически приемлемый эксципиент и терапевтически эффективное количество антитела.
14. Способ предупреждения образования тромба, заключающийся в том, что вводят терапевтически эффективное количество антитела по п.1, где антитело ингибирует образование тромбина, не оказывая непосредственного воздействия на другие параметры свертывания, такие как активация и агрегация тромбоцитов.
15. Способ по п.14, где способ предназначен для защиты от образования тромба при ишемическом ударе, тромботических осложнениях после пластической операции на сосудах или микрососудистой хирургии.
16. Способ снижения и лечения тромбоза глубоких вен (ТГВ), диссеминированного внутрисосудистого свертывания крови (ДВС), острого коронарного тромбоза или рака с признаками коагулопатии у пациента, заключающийся в том, что пациенту вводят терапевтически эффективное количество антитела по п.1.
17. Способ регуляции воспалительного ответа у пациента, заключающийся в том, что пациенту вводят терапевтически эффективное количество антитела по п.1.
18. Способ по п.17, где воспалительный ответ выбирают из ряда, включающего сепсис, трансплантаты кожи и вен и трансплантаты органов.
19. Антитело по п.1, где антитело можно применять для формирования нетромбогенного покрытия на поверхности медицинского устройства, где медицинское устройство приходит в контакт с кровью.
20. Набор, содержащий антитело по п.1.
21. Набор, содержащий последовательности ДНК, которые кодируют антитело по п.1.
22. Композиция для генной терапии, содержащая полинуклеотидную последовательность SEQ ID NO:2 или SEQ ID NO:4, которая кодирует антитело, аминокислотная последовательность которого представлена в SEQ ID NO:1 или SEQ ID NO:3, в сочетании с терапевтически эффективным количеством вектора, применяемого в генной терапии.
23. Антикоагулирующее антитело, где антитело представляет собой одноцепочечное антитело, которое связывается с большей аффинностью с комплексом FVIIa/ТФ, чем со свободным ТФ, и где антитело не конкурирует за связывание с ТФ с FVII и FX.
24. Антитело по п.23, где антитело содержит аминокислотную последовательность SEQ ID NO:1 или SEQ ID NO:3.
25. Полинуклеотидная последовательность, кодирующая антитело по п.23, где полинуклеотидная последовательность содержит нуклеотидную последовательность SEQ ID NO:2 или SEQ ID NO:4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37656602P | 2002-05-01 | 2002-05-01 | |
US60/376,566 | 2002-05-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004135306A true RU2004135306A (ru) | 2005-07-10 |
RU2345789C2 RU2345789C2 (ru) | 2009-02-10 |
Family
ID=29401364
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004135306/13A RU2345789C2 (ru) | 2002-05-01 | 2003-04-30 | Новые антитела к тканевому фактору в качестве антикоагулянтов |
RU2004135308/15A RU2320366C2 (ru) | 2002-05-01 | 2003-04-30 | Новые слитые белки тромбомодулина, обеспечивающие направленный перенос к тканевому фактору, в качестве антикоагулянтов |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004135308/15A RU2320366C2 (ru) | 2002-05-01 | 2003-04-30 | Новые слитые белки тромбомодулина, обеспечивающие направленный перенос к тканевому фактору, в качестве антикоагулянтов |
Country Status (29)
Country | Link |
---|---|
US (3) | US7250168B2 (ru) |
EP (2) | EP1549341B1 (ru) |
JP (2) | JP4460443B2 (ru) |
KR (2) | KR101080587B1 (ru) |
CN (2) | CN100563709C (ru) |
AR (1) | AR039515A1 (ru) |
AT (2) | ATE484524T1 (ru) |
AU (2) | AU2003225256B2 (ru) |
BR (2) | BR0304660A (ru) |
CA (2) | CA2483909A1 (ru) |
CR (1) | CR7584A (ru) |
DE (2) | DE60334538D1 (ru) |
DK (2) | DK1549341T3 (ru) |
EC (2) | ECSP045467A (ru) |
ES (2) | ES2354419T3 (ru) |
HK (1) | HK1080372A1 (ru) |
IL (3) | IL164733A0 (ru) |
MX (2) | MXPA04010851A (ru) |
NO (2) | NO20035848L (ru) |
NZ (2) | NZ536242A (ru) |
PE (1) | PE20040597A1 (ru) |
PL (2) | PL210582B1 (ru) |
PT (2) | PT1503785E (ru) |
RS (2) | RS102404A (ru) |
RU (2) | RU2345789C2 (ru) |
TW (1) | TWI343388B (ru) |
UA (2) | UA81114C2 (ru) |
WO (2) | WO2003092602A2 (ru) |
ZA (2) | ZA200409694B (ru) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60043728D1 (de) * | 1999-06-02 | 2010-03-11 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
AU7445900A (en) * | 1999-09-27 | 2001-04-30 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, nr12 |
AU2001296305B2 (en) | 2000-09-26 | 2007-12-06 | Duke University | RNA aptamers and methods for identifying the same |
US7579000B2 (en) | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
PE20040597A1 (es) * | 2002-05-01 | 2004-10-06 | Schering Ag | Proteinas de fusion de trombomodulina dirigidas al factor tisular como anticoagulantes |
EP1539235A2 (en) * | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
US7425328B2 (en) | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
US7833978B2 (en) * | 2004-02-20 | 2010-11-16 | Emory University | Thrombomodulin derivatives and conjugates |
PL1745062T3 (pl) | 2004-04-22 | 2014-10-31 | Regado Biosciences Inc | Ulepszone modulatory czynników krzepnięcia |
EP1889908A4 (en) | 2005-06-03 | 2012-04-25 | Mochida Pharm Co Ltd | PROTEIN FUSED WITH ANTI-CD14 ANTIBODY |
WO2008039206A2 (en) * | 2005-10-05 | 2008-04-03 | The Trustees Of The University Of Pennsylvania | Fusion proteins for inhibition and dissolution of coagulation |
WO2007115953A1 (en) * | 2006-04-07 | 2007-10-18 | Novo Nordisk Health Care Ag | Covalent factor vii-tissue factor complex |
CN101500608A (zh) | 2006-06-08 | 2009-08-05 | 中外制药株式会社 | 炎性疾病的预防或治疗药 |
RU2433829C2 (ru) * | 2006-10-06 | 2011-11-20 | Асахи Касеи Фарма Корпорейшн | Средство для лечения и/или улучшения состояния при диссеминированном внутрисосудистом свертывании |
WO2008121814A1 (en) | 2007-03-28 | 2008-10-09 | Ats Medical, Inc. | Method for inhibiting platelet interaction with biomaterial surfaces |
WO2009037297A2 (en) * | 2007-09-20 | 2009-03-26 | Bracco Imaging Spa | Method for the preparation of new oligoclonal antibodies |
MY185647A (en) | 2007-12-05 | 2021-05-27 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
US8333973B2 (en) * | 2008-01-02 | 2012-12-18 | The Trustees Of The University Of Pennsylvania | Targeting recombinant therapeutics to circulating red blood cells |
UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
CN102171237A (zh) * | 2008-08-14 | 2011-08-31 | 默沙东公司 | 使用蛋白a亲和色谱法纯化抗体的方法 |
US20110262466A1 (en) * | 2008-10-16 | 2011-10-27 | The Trustees Of The University Of Pennsylvania | Compositions containing thrombomodulin domains and uses thereof |
US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
EP2230251A1 (en) * | 2009-03-19 | 2010-09-22 | Bracco Imaging S.p.A | Antibodies specifically active in the coronary plaque and method for their identification |
CA2771328A1 (en) * | 2009-08-28 | 2011-03-03 | Bayer Healthcare Llc | Cofactors for thrombin activation of factor vii and uses thereof |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
MX348567B (es) | 2010-06-04 | 2017-06-20 | Tiumbio Co Ltd | Proteina de fusion que tiene actividad de factor vii. |
RS56599B1 (sr) | 2010-06-15 | 2018-02-28 | Genmab As | Konjugati humanog antitela sa lekom protiv tkivnog faktora |
KR20130099027A (ko) * | 2010-08-05 | 2013-09-05 | 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 | 혈전용해 및 응고억제 특성을 갖는 단백질 융합 구조물 |
RU2445365C1 (ru) * | 2010-11-03 | 2012-03-20 | Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") | Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты) |
US10544227B2 (en) | 2015-04-14 | 2020-01-28 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient |
WO2016176440A2 (en) * | 2015-04-28 | 2016-11-03 | Saint Louis University | Thrombin-thrombomodulin fusion proteins as protein c activators |
WO2017189943A1 (en) * | 2016-04-28 | 2017-11-02 | Saint Louis University | Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant |
PE20190966A1 (es) * | 2016-11-16 | 2019-07-08 | Bayer Healthcare Llc | Factor viii direccionado a los globulos rojos y metodo para su uso |
BR102017005783A2 (pt) * | 2017-03-21 | 2018-10-02 | Fund Butantan | processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos |
EP3861127A1 (en) * | 2018-10-04 | 2021-08-11 | Thrombosis and Coagulation AB | Method for the determination of protein s levels |
EP4062933A4 (en) | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | PHARMACEUTICAL PREPARATION COMPRISING AN ANTIBODY |
CN114686443B (zh) * | 2020-12-31 | 2023-11-03 | 广州万孚生物技术股份有限公司 | 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用 |
CN114686444B (zh) * | 2020-12-31 | 2024-05-31 | 广州万孚生物技术股份有限公司 | 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
ZA862768B (en) * | 1985-04-17 | 1986-12-30 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US5589173A (en) * | 1986-11-04 | 1996-12-31 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
US5437864A (en) * | 1987-03-31 | 1995-08-01 | The Scripps Research Institute | Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor |
US4912207A (en) * | 1987-05-06 | 1990-03-27 | Washington University | DNA clone of human thrombomodulin and portions thereof |
DK299087D0 (da) | 1987-06-12 | 1987-06-12 | Novo Industri As | Proteins and derivatives thereof |
US5298599A (en) * | 1988-12-30 | 1994-03-29 | Oklahoma Medical Research Foundation | Expression and purification of recombinant soluble tissue factor |
KR920701459A (ko) * | 1989-02-17 | 1992-08-11 | 코돈 | 트롬보모듈린의 가용성 유사체 |
US6063763A (en) * | 1989-04-28 | 2000-05-16 | Schering Aktiengesellschaft | Protease-resistant thrombomodulin analogs |
US5256770A (en) * | 1990-04-09 | 1993-10-26 | Schering Ag | Oxidation resistant thrombomodulin analogs |
US5466668A (en) * | 1989-04-28 | 1995-11-14 | Schering Aktiengesellschaft | Superior thrombomodulin analogs for pharmaceutical use |
KR930008093B1 (ko) * | 1990-08-03 | 1993-08-25 | 아사히가세이고오교 가부시끼가이샤 | 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물 |
US5843442A (en) * | 1990-10-22 | 1998-12-01 | Corvas International, Inc. | Blood coagulation protein antagonists and uses therefor |
US5506134A (en) * | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
JPH0578397A (ja) * | 1991-01-29 | 1993-03-30 | Sumitomo Pharmaceut Co Ltd | 血栓溶解タンパク質 |
JPH06133780A (ja) * | 1992-10-23 | 1994-05-17 | Sumitomo Pharmaceut Co Ltd | 新規なt−PA改変体 |
US5916874A (en) * | 1994-04-20 | 1999-06-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for treating liver injury |
US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
BR9909382A (pt) * | 1998-04-03 | 2000-12-05 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado |
JP2003527861A (ja) * | 2000-03-16 | 2003-09-24 | ジェネンテック・インコーポレーテッド | 増強した抗血液凝固能を持つ抗組織因子抗体 |
US6632791B1 (en) * | 2000-06-21 | 2003-10-14 | Schering Aktiengesellschaft | Thrombomodulin analogs for pharmaceutical use |
TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
EP1465998A2 (en) | 2002-01-08 | 2004-10-13 | Bayer HealthCare AG | Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy |
US7579000B2 (en) | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
PE20040597A1 (es) | 2002-05-01 | 2004-10-06 | Schering Ag | Proteinas de fusion de trombomodulina dirigidas al factor tisular como anticoagulantes |
-
2003
- 2003-04-30 PE PE2003000426A patent/PE20040597A1/es not_active Application Discontinuation
- 2003-04-30 MX MXPA04010851A patent/MXPA04010851A/es active IP Right Grant
- 2003-04-30 CA CA002483909A patent/CA2483909A1/en not_active Abandoned
- 2003-04-30 DE DE60334538T patent/DE60334538D1/de not_active Expired - Lifetime
- 2003-04-30 RU RU2004135306/13A patent/RU2345789C2/ru not_active IP Right Cessation
- 2003-04-30 TW TW092110159A patent/TWI343388B/zh not_active IP Right Cessation
- 2003-04-30 RU RU2004135308/15A patent/RU2320366C2/ru not_active IP Right Cessation
- 2003-04-30 WO PCT/US2003/013522 patent/WO2003092602A2/en active Application Filing
- 2003-04-30 NZ NZ536242A patent/NZ536242A/en unknown
- 2003-04-30 AR ARP030101529A patent/AR039515A1/es active IP Right Grant
- 2003-04-30 UA UA20041109787A patent/UA81114C2/uk unknown
- 2003-04-30 UA UA20041109788A patent/UA85996C2/ru unknown
- 2003-04-30 RS YU102404A patent/RS102404A/sr unknown
- 2003-04-30 JP JP2004501558A patent/JP4460443B2/ja not_active Expired - Fee Related
- 2003-04-30 KR KR1020047017458A patent/KR101080587B1/ko not_active IP Right Cessation
- 2003-04-30 DK DK03721974T patent/DK1549341T3/da active
- 2003-04-30 ES ES03721975T patent/ES2354419T3/es not_active Expired - Lifetime
- 2003-04-30 CA CA002483910A patent/CA2483910A1/en not_active Abandoned
- 2003-04-30 RS YUP-1045/04A patent/RS104504A/sr unknown
- 2003-04-30 AU AU2003225256A patent/AU2003225256B2/en not_active Ceased
- 2003-04-30 AU AU2003225255A patent/AU2003225255B2/en not_active Ceased
- 2003-04-30 CN CNB038157039A patent/CN100563709C/zh not_active Expired - Fee Related
- 2003-04-30 BR BR0304660-5A patent/BR0304660A/pt not_active IP Right Cessation
- 2003-04-30 MX MXPA04010795A patent/MXPA04010795A/es active IP Right Grant
- 2003-04-30 PL PL373960A patent/PL210582B1/pl not_active IP Right Cessation
- 2003-04-30 JP JP2004500787A patent/JP4567437B2/ja not_active Expired - Fee Related
- 2003-04-30 AT AT03721975T patent/ATE484524T1/de active
- 2003-04-30 CN CNB038157020A patent/CN100412090C/zh not_active Expired - Fee Related
- 2003-04-30 DK DK03721975.5T patent/DK1503785T3/da active
- 2003-04-30 EP EP03721974A patent/EP1549341B1/en not_active Expired - Lifetime
- 2003-04-30 EP EP03721975A patent/EP1503785B1/en not_active Expired - Lifetime
- 2003-04-30 AT AT03721974T patent/ATE427121T1/de active
- 2003-04-30 DE DE60326970T patent/DE60326970D1/de not_active Expired - Lifetime
- 2003-04-30 US US10/427,805 patent/US7250168B2/en not_active Expired - Fee Related
- 2003-04-30 ES ES03721974T patent/ES2323056T3/es not_active Expired - Lifetime
- 2003-04-30 PT PT03721975T patent/PT1503785E/pt unknown
- 2003-04-30 PL PL03373945A patent/PL373945A1/xx not_active Application Discontinuation
- 2003-04-30 WO PCT/US2003/013521 patent/WO2003093422A2/en active Application Filing
- 2003-04-30 NZ NZ536243A patent/NZ536243A/en unknown
- 2003-04-30 IL IL16473303A patent/IL164733A0/xx unknown
- 2003-04-30 KR KR1020047017456A patent/KR101013697B1/ko not_active IP Right Cessation
- 2003-04-30 PT PT03721974T patent/PT1549341E/pt unknown
- 2003-04-30 BR BR0304659-1A patent/BR0304659A/pt not_active IP Right Cessation
- 2003-12-30 NO NO20035848A patent/NO20035848L/no not_active Application Discontinuation
- 2003-12-30 NO NO20035849A patent/NO20035849L/no not_active Application Discontinuation
-
2004
- 2004-10-20 IL IL16473204A patent/IL164732A0/xx unknown
- 2004-10-20 IL IL164733A patent/IL164733A/en not_active IP Right Cessation
- 2004-11-24 CR CR7584A patent/CR7584A/es not_active Application Discontinuation
- 2004-11-30 ZA ZA200409694A patent/ZA200409694B/en unknown
- 2004-11-30 ZA ZA200409692A patent/ZA200409692B/xx unknown
- 2004-11-30 EC EC2004005467A patent/ECSP045467A/es unknown
- 2004-11-30 EC EC2004005468A patent/ECSP045468A/es unknown
-
2006
- 2006-01-06 HK HK06100300.9A patent/HK1080372A1/zh unknown
-
2007
- 2007-06-21 US US11/766,160 patent/US7622122B2/en not_active Expired - Fee Related
- 2007-06-21 US US11/766,155 patent/US7622457B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004135306A (ru) | Новые антитела к тканевому фактору в качестве антикоагулянтов | |
JP2005532045A5 (ru) | ||
JP2005538046A5 (ru) | ||
Wolberg | Thrombin generation and fibrin clot structure | |
JP2680192B2 (ja) | 血液凝固タンパク質のアンタゴニストおよびその利用方法 | |
EP0151239A2 (en) | Monoclonal antibodies specific to in vivo fragments derived from fibrinogen | |
US7754215B2 (en) | Antithrombotic therapy with antibodies binding to the A3 domain of von Willebrand factor (VWF) | |
CA2663547C (en) | Method of treating endothelial dysfunction | |
KR20000075734A (ko) | 혈액 응고를 억제하기 위한 항체 및 그의 사용 방법 | |
RU2006140407A (ru) | Антитела к гликопротеину vi и способы продуцирования и использования этих антител | |
DK1347730T3 (da) | Rekombinante anti-CD30-antistoffer og anvendelser deraf | |
Alegre et al. | Histopathologic and immunofluorescence study of skin lesions associated with circulating lupus anticoagulant | |
Idell et al. | Fibrin turnover in lung inflammation and neoplasia | |
JP2001095563A5 (ru) | ||
Muzykantov et al. | Immunotargeting of erythrocytes-bound streptokinase provides local lysis of a fibrin clot | |
DK1194528T3 (da) | Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof | |
RU2007136791A (ru) | Новые гибридные белки-активаторы плазминогена, используемые в качестве тромболитических средств | |
KR970701063A (ko) | 안티트롬빈제 용도로써 피브린-특이적 항체(fibrin-specific antibody for use as an antithrombotic agent) | |
Doolittle | Searching for differences between fibrinogen and fibrin that affect the initiation of fibrinolysis | |
Sugita et al. | Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions | |
Rinder et al. | Leukocyte effects of C5a-receptor blockade during simulated extracorporeal circulation | |
RU2302880C2 (ru) | Новый специфический механизм ингибирования адгезии тромбоцитов к коллагену | |
Speekenbrink et al. | Activation of the protein C system during cardiopulmonary bypass with and without aprotinin | |
Undas et al. | Factor XIII Val34Leu polymorphism and γ‐chain cross‐linking at the site of microvascular injury in healthy and coumadin‐treated subjects | |
Kontny et al. | Fibrin monomer antigen; a novel marker of mortality in acute myocardial infarction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner | ||
PD4A | Correction of name of patent owner | ||
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140501 |